Commodore reports 14.05M IKT holdings (includes warrants)

Inhibikase Therapeutics ownership update: Commodore Capital LP, Commodore Capital Master LP and affiliated managers report beneficial ownership of 14,054,940 shares of common stock as of March 31, 2026.

Rhea-AI Filing Summary

Inhibikase Therapeutics ownership update: Commodore Capital LP, Commodore Capital Master LP and affiliated managers report beneficial ownership of 14,054,940 shares of common stock as of March 31, 2026. This amount is composed of 5,397,488 shares of common stock plus warrants to purchase 5,290,799 Tranche 1 and 3,366,653 Tranche 2 warrants. The filers state a 9.9% beneficial ownership limitation applies. The ownership percentage is calculated using 132,032,636 shares outstanding as of March 31, 2026 from the issuer's Form 10-Q.

Insights

Corporate Governance Analyst

Large block disclosed with warrant components and ownership cap.

The filing lists an aggregate of 14,054,940 shares comprised of issued shares and two warrant tranches, and cites a 9.9% Beneficial Ownership Limitation. The limitation is expressly referenced for the Tranche 1 and Tranche 2 Warrants.

Implications depend on exercise choices and the ownership cap; subsequent filings or exercises would show whether the firm converts warrants into voting common stock.

Securities Structuring Specialist

Position includes mixed instrument exposure (shares + warrants).

The reported position breaks down into 5,397,488 shares, 5,290,799 Tranche 1 Warrants, and 3,366,653 Tranche 2 Warrants, with additional excluded warrant and pre-funded warrant amounts noted. The filing ties percentage calculations to the issuer's reported outstanding share base of March 31, 2026.

Monitoring future filings will clarify exercises, withheld/excluded instruments, and any changes to voting/dispositive power.

Key Figures

Aggregate beneficial ownership: 14,054,940 shares Common shares held: 5,397,488 shares Tranche 1 Warrants: 5,290,799 warrants +5 more

8 metrics

Aggregate beneficial ownership 14,054,940 shares as of March 31, 2026 (includes shares + warrants)

Common shares held 5,397,488 shares issued common stock component, March 31, 2026

Tranche 1 Warrants 5,290,799 warrants warrants to purchase common stock

Tranche 2 Warrants 3,366,653 warrants warrants to purchase common stock

Shares outstanding used 132,032,636 shares shares outstanding as of March 31, 2026 (Form 10-Q)

Beneficial ownership limit 9.9% limitation applied to the warrants

Excluded Tranche 2 Warrants 6,362,736 warrants excluded from aggregate but subject to limitation

Excluded Pre-Funded Warrant underlying shares 16,133,234 shares underlying Pre-Funded Warrant, excluded from aggregate

Key Terms

Beneficial Ownership Limitation, Tranche 1 Warrants, Pre-Funded Warrant, Schedule 13G/A

4 terms

Beneficial Ownership Limitation regulatory

"The Tranche 1 Warrants and Tranche 2 Warrants are subject to a beneficial ownership limitation of 9.99%"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Tranche 1 Warrants financial

"consisting of (i) 5,397,488 shares of Common Stock (ii) Tranche 1 Warrants to purchase up to 5,290,799 shares"

Pre-Funded Warrant financial

"The foregoing excludes 6,362,736 shares of the Tranche 2 Warrants and 16,133,234 shares of Common Stock underlying a Pre-Funded Warrant"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

Schedule 13G/A regulatory

"form_type: SCHEDULE 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Commodore Capital report in Inhibikase (IKT)?

Commodore reports beneficial ownership of 14,054,940 shares as of March 31, 2026, comprised of common shares plus Tranche 1 and Tranche 2 warrants. The filing ties the percentage to an outstanding share base of 132,032,636.

How is the 14,054,940 figure composed for IKT?

The aggregate includes 5,397,488 shares of common stock, 5,290,799 Tranche 1 Warrants, and 3,366,653 Tranche 2 Warrants, as stated in the filing dated March 31, 2026.

What is the Beneficial Ownership Limitation mentioned in the filing?

The filing states a 9.9% Beneficial Ownership Limitation applies to the Tranche 1 and Tranche 2 Warrants, limiting holdings the filers may exercise into common stock beyond that threshold.

Which outstanding share count did the filers use to compute percentage ownership?

They used 132,032,636 shares outstanding as of March 31, 2026, reported in the issuer's Form 10-Q referenced in the filing, to calculate ownership percentages.

Are there other warrants or pre-funded warrants referenced?

Yes; the filing excludes 6,362,736 shares of Tranche 2 Warrants and 16,133,234 shares underlying a Pre-Funded Warrant from the aggregate, noting they are subject to the Beneficial Ownership Limitation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:11 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Inhibikase Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45719W205

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Commodore Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14,054,940.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14,054,940.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

14,054,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Commodore Capital Master LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14,054,940.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14,054,940.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

14,054,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Robert Egen Atkinson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14,054,940.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14,054,940.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

14,054,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Michael Kramarz

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14,054,940.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14,054,940.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

14,054,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inhibikase Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1000 N. West Street, Suite 1200, Wilmington, DELAWARE, 19801.
Item 2.
(a)	Name of person filing: Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer."
(b)	Address or principal business office or, if none, residence: The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
(c)	Citizenship: See Item 4 of the cover page for each Filer.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 45719W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of the cover page for each Filer. This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm"), Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of March 31, 2026, the Firm may be deemed to beneficially own an aggregate of 14,054,940 shares Common Stock, $0.001 par value (the "Common Stock"), consisting of (i) 5,397,488 shares of Common Stock (ii) Tranche 1 Warrants to purchase up to 5,290,799 shares of Common Stock (the "Tranche 1 Warrants"), and (iii) Tranche 2 Warrants to purchase up to 3,366,653 shares of Common Stock (the "Tranche 2 Warrants"), of Inhibikase Therapeutics, Inc. (the "Issuer"). The Tranche 1 Warrants and Tranche 2 Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation"). The foregoing excludes 6,362,736 shares of the Tranche 2 Warrants and 16,133,234 shares of Common Stock underlying a Pre-Funded Warrant, which are subject to the Beneficial Ownership Limitation. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 132,032,636 Common Stock reported as issued and outstanding as of March 31, 2026 in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, plus (i) 5,290,799 Tranche 1 Warrants and (ii) 3,366,653 Tranche 2 Warrants.
(b)	Percent of class: See Item 11 of the cover page for each Filer.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of the cover page for each Filer.
	(ii) Shared power to vote or to direct the vote: See Item 6 of the cover page for each Filer.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the cover page for each Filer.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of the cover page for each Filer.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commodore Capital LP

Signature:	Michael Kramarz
Name/Title:	Managing Partner
Date:	05/15/2026

Commodore Capital Master LP

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	05/15/2026

Robert Egen Atkinson

Signature:	Robert Egen Atkinson
Name/Title:	Authorized Signatory
Date:	05/15/2026

Michael Kramarz

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	05/15/2026

Exhibit Information

Exhibit 1: Joint Filing Agreement